- Bullseye Trades
- Posts
- From crushed to climbing 📈
From crushed to climbing 📈
A comeback story in a chart...
Sponsored by Sica Media and Disseminated on Behalf of Relmada Therapeutics, Inc*
Markets opened the week strong, and I’ve got my eye on a biotech that’s been ripping back from the dead. Insiders are piling in, momentum’s hot, and it’s the kind of setup we don’t see often. Here’s the full story.
TODAY’S TOP ALERT!
Relmada Therapeutics (Nasdaq: RLMD)
👉 RLMD is TODAY’S #1 ALERT 👈
Good morning, Folks, Jeff Bishop here.
The markets were green across the board yesterday, with the Russell 2000, Dow, S&P 500, and Nasdaq all closing in the green.
Nice way to start the week!
I was also pleased to see my “tactical trade” idea reach an 8% high during the day and close in the green.
It didn’t quite reach the level of my six double-digit movers last week, but it was still a respectable “base hit.”
My “tactical” idea for today is a very impressive comeback story that’s rare in the early-stage pharma space.
Check out Relmada Therapeutics, Inc. (RLMD) on your trading platform.
The first thing that jumps out is a plunge in December 2024. The stock went from about $3.40 to the $0.40’s in just a few days…
That was due to a failed Phase 3 trial in its REL-1017 program targeting depression.
It’s the kind of setback that could crush an early-stage pharma company like RLMD.
Its stock stayed flat for several months after that, but in February and March, it acquired two promising candidates that had already reached Phase 2: NDV-01 targeting non-muscle invasive bladder cancer (NMIBC) and Sepranolone targeting compulsivity disorders.
Finally, in April, the stock had some life shocked back into it when the company reported positive initial data from the Phase 2 study of NDV-01 for NMIBC.
At the annual meeting of the American Urology Association (AUA), RLMD revealed that “90% of patients achieved high-grade disease-free status at any time point following treatment” and that treatment was well tolerated.
CEO Sergio Traversa said the company believes “NDV-01 has the potential to become the class-leading therapy for NMIBC across a wide spectrum of patients.”
Over the following two months, its stock tripled in price and then stayed steady until late August, when Mr. Traversa disclosed “the open-market purchase of 265,976 shares between August 26–28, 2025, at prices ranging from $0.62 to $0.74.”
💸 That brought his total holdings to more than 1,000,000 shares.
On top of that, the company’s Chief Medical Officer of Urology, Raj S. Pruthi, MD, “reported on August 29 that he had purchased 55,000 shares of the company’s common stock.”
Mr. Traversa said his “decision to make this substantial additional investment reflects my strong conviction that Relmada remains significantly undervalued by the market.”
Investors seem to have agreed. From August 26 through yesterday’s close, the stock has risen 152%. Folks, that’s over less than three weeks.
And with a 5% gain yesterday and positive action after-hours, I’m watching RLMD today to see where this momentum takes it.
👉 RLMD is TODAY’S #1 ALERT 👈
Aside from the insider buying, the other thing that’s helped boost RLMD is this September 10 shareholder letter.
It’s worth reading in full to get a sense of where the company’s at, but here are some highlights that jumped out at me…
NDV-01 has had strong Phase 2 results beyond what was reported at the AUA meeting, including a 91% complete response (CR) rate at any time point following treatment.
The condition it’s targeting, NMIBC, affects approximately 600,000 patients in the U.S.
RLMD is “actively preparing to initiate a Phase 3 registrational trial in the first half of 2026.”
The letter also noted that the company had added two experts in bladder cancer: Raj S. Pruthi, MD as Chief Medical Officer–Oncology and Yair Lotan, MD as Chair of the Clinical Advisory Board.
It said “Their expertise will be invaluable as we advance the program toward late-stage development.”
The company said that Sepranolone had shown promise in Tourette’s syndrome, which suggests it “may hold promise as a therapy for compulsive disorders.”
It said that “In the first half of 2026, we plan to initiate a Phase 2 study in [Prader-Willi Syndrome], a rare genetic disorder affecting 350,000–400,000 people worldwide and characterized by compulsive behaviors such as hyperphagia (obsessive eating).”
That letter is a great overview, but for a deeper dive on some of the science especially, be sure to check out this investor presentation released this month.
One important thing it notes is that the company was sitting on $21 million in cash and no debt as of June 30.
And of course, always approach your trading in a responsible manner, remembering that trading is very risky. Nothing is ever guaranteed, so never trade with more than you can afford to lose.
Please read the full disclaimer at the bottom of this email as well, so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.
Bottom line: RLMD has ripped 152% over the past three weeks, and with a 5% gain yesterday and positive action after-hours, it’s not showing signs of stalling.
I’m watching it today for another move up. No guarantees, naturally, but be sure to have RLMD on your radar to see how it plays out!
To Your Success,
Jeff Bishop
*DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/
Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”
Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from Sica Media for advertising Relmada Therapeutics, Inc for a one day marketing program starting on September 16, 2025. It might seem obvious, but while our client claims not to own any shares in Relmada Therapeutics, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.
Now, diving right into Relmada Therapeutics, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.
Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear,
Neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a securities broker-dealer, broker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulatory authority, or any self-regu1atory organization.
So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.